Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
07 nov. 2023 06h30 HE
|
Verve Therapeutics
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and...
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
31 oct. 2023 06h01 HE
|
Verve Therapeutics
BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
23 oct. 2023 06h30 HE
|
Verve Therapeutics
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
26 sept. 2023 06h30 HE
|
Verve Therapeutics
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
21 sept. 2023 16h05 HE
|
Verve Therapeutics
BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
18 sept. 2023 06h30 HE
|
Verve Therapeutics
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
10 août 2023 06h30 HE
|
Verve Therapeutics
heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and...
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
03 août 2023 06h30 HE
|
Verve Therapeutics
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
15 juin 2023 06h30 HE
|
Verve Therapeutics
Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and...
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
01 juin 2023 06h30 HE
|
Verve Therapeutics
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...